1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617–627. PMID:
15939839.
2. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011;130:226–238. PMID:
21334376.
3. Leonard BE. The concept of depression as a dysfunction of the immune system. Curr Immunol Rev 2010;6:205–212. PMID:
21170282.
4. Leonard BE, Song C. Stress and the immune system in the etiology of anxiety and depression. Pharmacol Biochem Behav 1996;54:299–303. PMID:
8728571.
5. Miller AH. Neuroendocrine and immune system interactions in stress and depression. Psychiatr Clin North Am 1998;21:443–463. PMID:
9670236.
6. Song C, Dinan T, Leonard BE. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord 1994;30:283–288. PMID:
7516941.
7. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012;139:230–239. PMID:
21872339.
8. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000;157:683–694. PMID:
10784457.
9. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 2011;25:181–213. PMID:
20970492.
10. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004;56:819–824. PMID:
15576057.
11. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007;21:153–160. PMID:
17088043.
12. Dunn AJ, Swiergiel AH. The role of cytokines in infection-related behavior. Ann N Y Acad Sci 1998;840:577–585. PMID:
9629284.
13. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 2005;29:891–909. PMID:
15885777.
14. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446–457. PMID:
20015486.
15. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009;71:171–186. PMID:
19188531.
16. Lieb J, Karmali R, Horrobin D. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot Med 1983;10:361–367. PMID:
6574523.
17. Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993;150:1189–1193. PMID:
8328562.
18. Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009;66:287–292. PMID:
19268915.
19. Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:445–450. PMID:
17976882.
20. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011;36:2452–2459. PMID:
21796103.
21. American Psychiatric Association. American Psychiatric Association Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th Text Version Ed. Washington, DC: American Psychiatric Association; 2000.
22. Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ, et al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA 2006;296:1609–1618. PMID:
17018806.
23. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG, et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000;11:215–219. PMID:
10683861.
24. Myung W, Lim SW, Kim S, Kim H, Chung JW, Seo MY, et al. Serotonin transporter genotype and function in relation to antidepressant response in Koreans. Psychopharmacology (Berl) 2013;225:283–290. PMID:
22885912.
25. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62. PMID:
14399272.
26. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278–296. PMID:
6080235.
27. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010;15:473–500. PMID:
18982004.
28. Leo R, Di Lorenzo G, Tesauro M, Razzini C, Forleo GB, Chiricolo G, et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry 2006;67:1760–1766. PMID:
17196057.
29. Suarez EC, Krishnan RR, Lewis JG. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom Med 2003;65:362–368. PMID:
12764208.
30. Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, et al. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res 2014;20:1366–1374. PMID:
24423611.
31. Freedman JE. CD40-CD40L and platelet function: beyond hemostasis. Circ Res 2003;92:944–946. PMID:
12750303.
32. Schonbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res 1997;81:448–454. PMID:
9285647.
33. Schonbeck U, Mach F, Libby P. CD154 (CD40 ligand). Int J Biochem Cell Biol 2000;32:687–693. PMID:
10856699.
34. Neubauer H, Petrak F, Zahn D, Pepinghege F, Hagele AK, Pirkl PA, et al. Newly diagnosed depression is associated with increased beta-thromboglobulin levels and increased expression of platelet activation markers and platelet derived CD40-CD40L. J Psychiatr Res 2013;47:865–871. PMID:
23583028.
35. Anisman H, Merali Z. Cytokines, stress, and depressive illness. Brain Behav Immun 2002;16:513–524. PMID:
12401465.
36. Griffiths J, Ravindran AV, Merali Z, Anisman H. Dysthymia: a review of pharmacological and behavioral factors. Mol Psychiatry 2000;5:242–261. PMID:
10889527.
37. Nierenberg AA, Trivedi MH, Fava M, Biggs MM, Shores-Wilson K, Wisniewski SR, et al. Family history of mood disorder and characteristics of major depressive disorder: a STAR
*D (sequenced treatment alternatives to relieve depression) study. J Psychiatr Res 2007;41:214–221. PMID:
16690084.
38. Power RA, Keers R, Ng MY, Butler AW, Uher R, Cohen-Woods S, et al. Dissecting the genetic heterogeneity of depression through age at onset. Am J Med Genet B Neuropsychiatr Genet 2012;159b:859–868. PMID:
22915352.
39. Fagiolo U, Cossarizza A, Scala E, Fanales-Belasio E, Ortolani C, Cozzi E, et al. Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol 1993;23:2375–2378. PMID:
8370415.
40. Molteni M, Della Bella S, Mascagni B, Coppola C, De Micheli V, Zulian C, et al. Secretion of cytokines upon allogeneic stimulation: effect of aging. J Biol Regul Homeost Agents 1994;8:41–47. PMID:
7863811.
41. Paganelli R, Scala E, Quinti I, Ansotegui IJ. Humoral immunity in aging. Aging (Milano) 1994;6:143–150. PMID:
7993921.
42. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, et al. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol 2008;18:230–233. PMID:
17681762.
43. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001;11:203–208. PMID:
11418279.
44. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res 2007;41:326–331. PMID:
16870211.
45. Lehto SM, Niskanen L, Herzig KH, Tolmunen T, Huotari A, Viinamaki H, et al. Serum chemokine levels in major depressive disorder. Psychoneuroendocrinology 2010;35:226–232. PMID:
19592174.
46. Kunkel SL, Standiford T, Kasahara K, Strieter RM. Interleukin-8 (IL-8): the major neutrophil chemotactic factor in the lung. Exp Lung Res 1991;17:17–23. PMID:
2013270.
47. Grassi-Oliveira R, Brieztke E, Teixeira A, Pezzi JC, Zanini M, Lopes RP, et al. Peripheral chemokine levels in women with recurrent major depression with suicidal ideation. Rev Bras Psiquiatr 2012;34:71–75. PMID:
22392392.
48. Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, et al. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007;2007:76396PMID:
18317531.
49. de Haas AH, van Weering HR, de Jong EK, Boddeke HW, Biber KP. Neuronal chemokines: versatile messengers in central nervous system cell interaction. Mol Neurobiol 2007;36:137–151. PMID:
17952658.
50. Madrigal JL, Leza JC, Polak P, Kalinin S, Feinstein DL. Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J Neurosci 2009;29:263–267. PMID:
19129402.
51. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680–684. PMID:
16491133.
52. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, et al. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009;26:607–611. PMID:
19496103.
53. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 2012;141:308–314. PMID:
22516310.
54. Magalhaes PV, Jansen K, Stertz L, Ferrari P, Pinheiro RT, da Silva RA, et al. Peripheral eotaxin-1 (CCL11) levels and mood disorder diagnosis in a population-based sample of young adults. J Psychiatr Res 2014;48:13–15. PMID:
24182965.
55. Brambilla F, Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr Scand 1998;97:309–313. PMID:
9570493.
56. Brambilla F, Monteleone P, Maj M. Interleukin-1beta and tumor necrosis factor-alpha in children with major depressive disorder or dysthymia. J Affect Disord 2004;78:273–277. PMID:
15013254.
57. Diniz BS, Teixeira AL, Talib LL, Mendonca VA, Gattaz WF, Forlenza OV. Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. J Psychiatr Res 2010;44:917–920. PMID:
20338581.